Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanaria procures US grant for malaria research

This article was originally published in Scrip

Executive Summary

Sanaria, a private company based in Rockville, Maryland, and the University of Maryland Biotechnology Institute have been awarded a $600,000 phase 1 small business innovation research (SBIR) grant from the US National Institute of Allergy and Infectious Diseases to support R&D efforts to genetically engineer mosquitoes that can enhance Sanaria's whole-parasite malaria vaccine production process. Sanaria plans to begin the first human trials of its malaria vaccine in 2009. It claims that its goal is to develop and commercialise a malaria sporozoite vaccine against Plasmodium falciparum.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts